BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30136667)

  • 1. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
    Chivukula MV; Tisocki K
    WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region.
    Chivukula MV; Tisocki K
    WHO South East Asia J Public Health; 2018 Sep; 7(2):62-66. PubMed ID: 30136662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strengthening regional commitment to ensuring access to medical abortion medicines in WHO's South-East Asia region: report of a participatory assessment and workshop.
    Upadhyay MT; Fusire T; Loi UR; Sorhaindo A; Salahuddin M; Hossain MA; Tshomo T; Mulati E; Daisy L; Anggraweni DP; Gultom T; Indrawati F; Jenyfa M; Than MM; Bhattarai B; Moonasinghe L; Mathota C; Jitruknatee A; Cham C; Ganatra B; Raina N
    Reprod Health; 2024 May; 20(Suppl 1):191. PubMed ID: 38760864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO.
    Piggott T; Nowak A; Brignardello-Petersen R; Cooke GS; Huttner B; Schünemann HJ; Persaud N; Magrini N; Moja L
    BMJ Open; 2022 Feb; 12(2):e053349. PubMed ID: 35144950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to mifepristone, misoprostol, and contraceptive medicines in eight countries in the Eastern Mediterranean Region: descriptive analyses of country-level assessments.
    Afifi M; Hemachandra N; Sikandar Q; Hajjeh R; Loi UR; Läser L; Qato D; Abdul ZS; Chikvaidze P; Abbas RAR; Al-Kinani K; Hasan H; El-Kak F; Rady A; Brngali O; Hashem M; Bezad R; Amine C; Hafid H; Afzal S; Zaidi R; Thom E; Uzma Q; Al-Masri H; Qamar ZA; Ghanem B; Ward IA; Shaar AN; Farah U; Mohamed YO; Umar AU; Eladawy M
    Reprod Health; 2024 Jun; 20(Suppl 1):192. PubMed ID: 38835050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential medicines for cancer: WHO recommendations and national priorities.
    Robertson J; Barr R; Shulman LN; Forte GB; Magrini N
    Bull World Health Organ; 2016 Oct; 94(10):735-742. PubMed ID: 27843163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative evaluation of essential medicines lists: the South African case study.
    Perumal-Pillay VA; Suleman F
    BMC Health Serv Res; 2016 Dec; 16(1):687. PubMed ID: 27955710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
    Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
    Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders.
    Papola D; Ostuzzi G; Todesco B; Gastaldon C; Hanna F; Chatterjee S; van Ommeren M; Barbui C
    Lancet Psychiatry; 2023 Oct; 10(10):809-816. PubMed ID: 37475123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access and use of WHO essential medicines in Italy.
    Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
    Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists.
    Piggott T; Moja L; Jenei K; Kredo T; Skoetz N; Banzi R; Trapani D; Leong T; McCaul M; Lavis JN; Akl EA; Nonino F; Iorio A; Laurson-Doube J; Huttner BD; Schünemann HJ
    J Clin Epidemiol; 2024 Feb; 166():111241. PubMed ID: 38123105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
    Mahmić-Kaknjo M; Marušić A
    Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer medicines in Pakistan: An analysis of essential medicines lists.
    Shukar S; Anjum R; Zhang J; Babar ZU; Mobeen I; Yang C
    J Oncol Pharm Pract; 2024 Jan; 30(1):46-54. PubMed ID: 37006130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
    Naicker I; Suleman F; Perumal-Pillay VA
    J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
    Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
    PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists.
    Jarvis JD; Woods H; Bali A; Oronsaye E; Persaud N
    PLoS One; 2019; 14(8):e0220781. PubMed ID: 31398195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
    Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
    ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential medicines lists for children of WHO, India, South Africa, and EML of China: A comparative study.
    Liu D; Cheng J; Zhang LL; Li YP; Zeng LN; Zhang C; Gui G
    J Evid Based Med; 2017 Nov; 10(4):271-280. PubMed ID: 28276634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region.
    Mehrtash H; Laing R; Wirtz VJ
    East Mediterr Health J; 2018 Jul; 24(5):427-434. PubMed ID: 30043961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.